{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 42,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 22,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/8",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.36,
        "w": 0.27,
        "x": 0.059,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Total Company Revenue Millions USD 934 941 2Q21 2Q22",
      "attrs": {},
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "626305e7-415c-4661-a20f-ed7a531871a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.202,
        "x": 0.35,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Vision Care $589M 64% 36% Contact Lens Consumer",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f883f03-0be5-424c-ba74-beede73778b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.202,
        "x": 0.57,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Surgical $184M 55% 27% 18% Implantables Equipment Consumables/Other",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3f54614-452c-464c-b961-8623407dd9db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.202,
        "x": 0.79,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Ophthalmic Pharmaceuticals $168M 41% 59% U.S. International",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be74dc11-66e3-4327-9555-ae9b20d94634",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.27,
        "x": 0.05,
        "y": 0.71
      },
      "kind": "list",
      "text": "Driven by strong demand across key franchises and durable portfolio with high brand equity\nStrong performance notwithstanding FX headwind of $46M",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "512f85e1-cb56-42a2-b129-afced2b2b52c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.202,
        "x": 0.79,
        "y": 0.71
      },
      "kind": "list",
      "text": "U.S. impacted by tail end of LOE products and generic performance and competition\nVyzulta® saw 36% TRx growth³; Approved in 18 countries, including Lebanon in 2Q22; Launched in Thailand in 2Q22 and upcoming launch in Brazil expected in 4Q22\nSubmitted NDA for NOV03; Filing acceptance expected in 3Q22",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f22c78bb-9747-4531-8f88-c0ee9cebc714",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.202,
        "x": 0.35,
        "y": 0.71
      },
      "kind": "list",
      "text": "Strong demand for key franchises: Lumify® (+21% reported revenue growth), BioTrue® Solutions Franchise (+39% reported revenue growth) and Ocuvite® + PreserVision® (+7% reported revenue growth)\nOpportunity to build out specialty contact lens portfolio with new launch of Revive ™; brand expansion with launch of BioTrue® Hydration Plus Multi-Purpose Solution",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2be649a-77e5-4585-9c10-cab74d048948",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.202,
        "x": 0.57,
        "y": 0.71
      },
      "kind": "list",
      "text": "Continued market recovery / backlog of elective surgeries\nDemand for consumables (+3% reported revenue growth; +13% organic revenue growth1.2) and implantables (+4% reported revenue growth; +10% organic revenue growth1.2)\nIncrease in procedure volume in Western Europe driving growth in International Surgical",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc24a65d-f0eb-4530-acbd-af03df83361a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.08,
        "x": 0.79,
        "y": 0.67
      },
      "kind": "metric",
      "text": "(10%)",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "093c0075-bfe8-4075-b02e-39ebd6b13ad5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.27,
        "x": 0.05,
        "y": 0.61
      },
      "kind": "metric",
      "text": "+6% organic revenue1,2 growth",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29ffb006-ca30-4e65-8236-9aa27975f1e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.08,
        "x": 0.57,
        "y": 0.67
      },
      "kind": "metric",
      "text": "+7%",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6de6ae80-3b5a-40c3-900c-ac3a262c1159",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.102,
        "x": 0.35,
        "y": 0.67
      },
      "kind": "metric",
      "text": "+11%",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9147e40-b96e-4936-915a-ae5e12e8a4e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.656,
        "x": 0.158,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.\n3. IQVIA NPA monthly.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83f580cd-a52f-49f0-b37e-a07f682a264e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.889,
        "x": 0.046,
        "y": 0.08
      },
      "kind": "title",
      "text": "2Q22 Financial Highlights & Segment Drivers - Revenue",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb766a57-6647-41e8-bbb9-460e6104557f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "a9c32713-f618-4ebe-b154-ede3aef95b9b",
      "evidence": "chart/donut: Surgical $184M 55% 27% 18% Implantables Equipment Consumables/Other",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0820f93-74dc-4006-a0cc-2e2499a07167",
      "evidence": "The loop opens on slide 6 and closes on slide 15, showcasing the company's opportunities",
      "position": 0,
      "objective": "Highlighting the benefits of a standalone Bausch + Lomb",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}